VEGFA and neoplasm: In the last decades, several drugs which target the tumor vasculature and inhibit tumor angiogenesis have been discovered2 and some antiangiogenic agents are approved for clinical use, such as humanized anti-VEGF-A antibody bevacizumab, tyrosine kinase inhibitors sorafenib and sunitinib3.